Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report
Enfortumab vedotin (EV) is an antibody-drug conjugate and a promising agent for metastatic urothelial carcinoma (mUC). However, evaluations in end-stage renal disease patients undergoing hemodialysis are unreported. Here, we report such a case. A 74-year-old woman with mUC, on hemodialysis for complete urinary tract extirpation, was diagnosed with multiple pulmonary metastases after treatment with gemcitabine-carboplatin followed by pembrolizumab. As third-line therapy, she received a standard dose of EV. She achieved complete response after 2 cycles without grade 3 or higher adverse events, demonstrating the utility of EV in this setting.
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report ; volume:16 ; number:1 ; year:2023 ; pages:429-433 ; extent:5
Case reports in oncology ; 16, Heft 1 (2023), 429-433 (gesamt 5)
- Creator
-
Isoda, Bunpei
Shiga, Masanobu
Kandori, Shuya
Nagumo, Yoshiyuki
Yoshino, Takayuki
Ikeda, Atsushi
Kawahara, Takashi
Kimura, Tomokazu
Negoro, Hiromitsu
Hoshi, Akio
Mathis, Bryan J.
Nishiyama, Hiroyuki
- DOI
-
10.1159/000530780
- URN
-
urn:nbn:de:101:1-2023122723470807831129
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Isoda, Bunpei
- Shiga, Masanobu
- Kandori, Shuya
- Nagumo, Yoshiyuki
- Yoshino, Takayuki
- Ikeda, Atsushi
- Kawahara, Takashi
- Kimura, Tomokazu
- Negoro, Hiromitsu
- Hoshi, Akio
- Mathis, Bryan J.
- Nishiyama, Hiroyuki
Other Objects (12)
A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
Enfortumab Vedotin-Induced Febrile Neutropenia and Hyperglycemia Successfully Treated with Multidisciplinary Treatment Including Continuous Hemodialysis Filtration and Insulin Injection in a Patient with Chemo-Resistant Metastatic Urothelial Carcinoma: A Case Report
Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study
Micropapillary Variant of Urothelial Carcinoma in a Hemodialysis Patient
Recent advances in medical therapy for metastatic urothelial cancer
Enhanced metastatic potential in the MB49 urothelial carcinoma model
Clinical Pharmacology of the Antibody–Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors
Polatuzumab Vedotin: First Global Approval
Pembrolizumab-Induced Severe Neuropathy in a Patient with Metastatic Urothelial Carcinoma after Achieving Complete Response: Guillain-Barré Syndrome-Like Onset
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan
Brentuximab Vedotin als Erstlinientherapie : Hodgkin-Lymphom
A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
Enfortumab Vedotin-Induced Febrile Neutropenia and Hyperglycemia Successfully Treated with Multidisciplinary Treatment Including Continuous Hemodialysis Filtration and Insulin Injection in a Patient with Chemo-Resistant Metastatic Urothelial Carcinoma: A Case Report
Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study
Micropapillary Variant of Urothelial Carcinoma in a Hemodialysis Patient
Recent advances in medical therapy for metastatic urothelial cancer
Enhanced metastatic potential in the MB49 urothelial carcinoma model
Clinical Pharmacology of the Antibody–Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors
Polatuzumab Vedotin: First Global Approval
Pembrolizumab-Induced Severe Neuropathy in a Patient with Metastatic Urothelial Carcinoma after Achieving Complete Response: Guillain-Barré Syndrome-Like Onset
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan
Brentuximab Vedotin als Erstlinientherapie : Hodgkin-Lymphom
A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
Enfortumab Vedotin-Induced Febrile Neutropenia and Hyperglycemia Successfully Treated with Multidisciplinary Treatment Including Continuous Hemodialysis Filtration and Insulin Injection in a Patient with Chemo-Resistant Metastatic Urothelial Carcinoma: A Case Report
Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study
Micropapillary Variant of Urothelial Carcinoma in a Hemodialysis Patient
Recent advances in medical therapy for metastatic urothelial cancer
Enhanced metastatic potential in the MB49 urothelial carcinoma model
Clinical Pharmacology of the Antibody–Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors
Polatuzumab Vedotin: First Global Approval
Pembrolizumab-Induced Severe Neuropathy in a Patient with Metastatic Urothelial Carcinoma after Achieving Complete Response: Guillain-Barré Syndrome-Like Onset
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan